DISHMAN PHARMACEUTICALS AND CHEMICALS LIMITED
CIN:1.242306.11983PLC006329 Email ID: dishman@dishmangroup.com Web: www.dishmangroup.com
Bhadr-Raj Chambers, Swastik Cross Roads, Navrangpura, Ahmedabad-380 009 Phone No: 079-26443053 Fax No: 079-26420198
Part I: Statement of Standalone / Consolidated Unaudited Results for Quarter Ended 30-06-2015

6		4	ō	1	:	1 2		-1		70		4 10		۵	Τ	Τ	Τ			Τ		12	丁	Τ	<u> </u>	Г	Z G	1
Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13+14+15)	15 Minority Interest	14 Income from Associates	Net Profit (Loss) for the period (11-12)	Extraordinary Items (net of tax expense)	after tax (9-10)	Not Brothill Co. Co.	before tax (7+8)	Exceptional items	finance costs but before exceptional items (5-6)	Profit/(Loss) from ordinary articles after	before finance costs and exceptional items (3+4)	Other Income	Other Income, finance costs and exceptional items (1-2)	Droff / / oco from Occasion	g) Omer Expenditure	t) Depreciation and amortisation expense	e) Employee benefits expense	d) Power & Fuel	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	b) Purchase of stock-in-trade	a) Cost of material consumed	-	Total Income from operations (net)	a) Net sales/income from operations (Net of excise duty) b) Other Operating Income	Income From Operations		PARTICULARS	
800.77		1	800.77		800.77	431.18	1,231.95	•	1,241.00	2,592.56	3,824.57	950.78	2,873.73	10,525.47	1,398.30	1,128.93	1,502.01	835.91	1,136.65	1	4,523.67		43 399 20	13,371.70		Unaudited	For The Quarter ended 30-06-2015	
2,195.39	-		2,195.39	•	2,195.39	2,772.11	4,967.50	t	4,307,30	1,500.58	6,468.08	3,101.74	3,366.34	12,680.16	917.40	1,059.86	1,443.66	510.39	1,517.10	2,423.79	4,807.96	10,070,00	40.62	16,005.88		Unaudited	Preceding Quarter ended 31-03-2015	STAND
157.73			157.73	,	157.73	239.84	397.57	1	387,37	1,529.15	1,926.72	389.51	1,537.21	7,461.23	1,018.34	1,501.57	1,351.97	756.21	(1,525.89)	66.27	4.292.76	0,350,44	31.65	8,966.79		Unaudited	Corresponding Quarter ended 30-06-2014	STANDALONE
5,847.83	-	-	5,847.83		5,847.83	4,534.76	10,382.59		10,382,59	6,813.28	17,195.87	6,699.77	10,496.10	37,373.21	3,964.55	4,413,24	5,887.92	3.166.98	(2,269.23)	2,586.93	19.622.82	47,865,31	124.13	47,745.18		Audited	For the Year ended 31-03-2015	
3,775.82		0.10	3,775,72	•	3,775.72	1,298.56	5,074.28	,	5,074,28	3,187.08	8,261.36	411.61	7,849.75	32,205.00	8,967.97	2.593.22	12.406.89	-	(1,905.97)		10 142 80	40,054.75	51.12	40,003.63		Unaudited	For The Quarter ended 30-06-2015	
3,860.56		1.35	3,859,21		3,859.21	1,396.52	5,255.73	-	5,255.73	2,498.83	7,754.56	7,271.90	482.66	41,883.84	7,961.24	7 067 30	8 427 37		3,504.01	2 423 79	10 500 13	42,366.50	304.19	42,062.31		Unaudited	For The Preceding Quarter ended 31-03-2015	SOL
2,381,42		3.71	2,377.71		2,377.71	500.99	2,878.70	-	2,878.70	2,052.42	4,931.12	445.24		31,785.15	7,093.10	3.057.58	11 188 90		(8,383.42)	66.27		36,271.03		36,155.98		Unaudited	For The Corresponding Quarter ended 30-06-2014	DAT
11,980.90	1.00	4 86	11,976.04	•	11,976.04	3,943.81	15,919.85		15,919,85	8,970.84	24,890.69	8,599.63	16,291.06	141,227.70	30.335.47	15,020.07	42 720 84		(4,259.00)	2 586 03	EE 170 OF	157,518.76	1,483.78	156,034,98		Audited	For the Year ended 31-03-2015	



(Rupees in Lacs)

	_	_	_		_				_	_		,		_																
	L	Ļ	L	-		<u></u>	100		L					╛		Ļ	N		L	_	Α		밁			Ĺ		19	9	17
Remaining unresolved at the end of the quarter	Disposed during the quarter	Received during the quarter	Pending at the beginning of the quarter	INVESTOR COMPLAINTS		- Percentage of Shares (as a % of the total share capital of the company)	shareholding of promoter & promoter group)	- Percentage of Shares (as a % of the total	- Number of Shares	b) Non-encumbured	- Percentage of Shares (as a % of the total share capital of the company)	shareholding of promoter & promoter group)	- Percentage of Shares (as a % of the total		- Number of Shares	a) Pledged/Encumbured	Promoters and promoter group Shareholding	- Percentage of Shareholding	- Number of Equity Shares	Public Shareholding	PARTICULARS OF SHAREHOLDING		Part II · Select Information for the Organiar anded 20.06. 2045	See accompanying notes to the financial results	ii) Diluted EPS (Not annualised)	i) Basic EPS (Not annualised)	Extraordinary Items) (of Rs. 2 each)	Basic and Diluted EPS (before & after	Reserves Excluding Revaluation Reserves as per balance sheet of previous accounting year	17 Paid -up Equity Share Capital (Face Value of Rs 2/- per equity share)
Z	N.	Nii.	Z	Quarter ended 30-06-2015		50.80%		82.74%	40,994,449		10.60%			17.26%	8,554,000			38.60%	31,148,687			-	20_06_204.5		0.99	0.99		,		1,613.94
НА	RAI	1		-		42.79%		69.69%	34,531,949		18.61%			30.31%	15,016,500			38.60%	31,148,687						2.72	2.72				1,613.94
HA AHMCDABAD	_	~~`	STICALS A			37.37%		60.87%	30,159,028		24.03%			39.13%	19.389.421			38.60%	31,148,687						0.20	0.20		,	•	1,613.94
- MI				٠		42.79%		69.69%	34,531,949		18.61%			30.31%	15.016.500			38.60%	31,148,687						7.25	7.25			82,028.71	1,613.94
						50.80%		82.74%	40,994,449		10.60%			17.26%	8,554,000			38.60%	31,148,687						4.68	4.68		1		1,613.94
						42.79%		69.69%	34,531,949		18.61%			30.31%	15,016,500			38.60%	31,148,687						4.78	4.78				1,613.94
						37.37%		60.87%	30,		24.03%			39.13%	19,389,421			38.60%	31,148,687						2.95	2.95		1	1	1,613.94
						42.79%		69,69%	34,531,949		18.61%			30.31%	15,016,500			38.60%	31,148,687						14.84	14.84			122,164.56	1,613.94



	Plac	*		T	Τ	T	မ									М					1	١		N S		
	Place: Ahmedabad Date: 31st August 2015	Includes Forex (Loss) / Gain	Total	(c) Unallocable	(b) Others	(a) CRAMS	Capital Employed (Segment Assets-	Total Profit/(Loss) Before Tax	allocable income	ii) Other un-allocable expenditure net off un-	Less: i) Interest	Total	(b) Others*	(a) CRAMS*	tax and interest from each segment)	Segment Results (Profit/(Loss) before	Net Sales /Income from Operation	Less: Inter-segment Revenue	Total	(b) Others	(a) CRAMS	Seament Revenue		PARTICULARS		Segment wise Revenue, Result and Capital Employed
			152,615.34	27,263.65	55.005.06	70.346.63		1,231.95			2,592.56	3,824.51	1,036.22	2,788.29			13,371.70		13,371.70	4,116.36	9,255.34		Unaudited	30-06-2015	For The Quarter	al Employed
			149,877.24	24,549.30	55,911.10	69,416,84		4,967.50		1	1,500.58	6,468.08	2,335.30	4,132.78		-	16,005,88	1	16,005.88	5,861.46	10,144.42		Unaudited	31-03-2015	For The Preceding	
Junan Pi			135,016.47	20,680.94	52,844.44	61,491.09		397.57		•	1,529.15	1,926.72	333.28	1,593.44			8,966.79		8,966.79	3,544.72	5,422.07		Unaudited	30-06-2014	For The Corresponding	
SO THE STATE OF SAME	TIOALS ALL THE		149,877.24	24,549.30	55,911.10	69,416.84		10,382.59		-	6,813.28	17,195.87	4,490.76	12,705.11			47,745.18		47,745.18	17,912.93	29,832.25		Audited	31-03-2015	For the Year	
	1		215,054.85	25,122.00	82,915.51	107,017.34		0,074.30	5074.20	(0.10)	3,187.08	8,261.36	3,102.83	5,158.43			40,003.63		40,003.63	14,815.59	25,188.04		Unaudited	30-06-2015	For The Quarter	
45	Arpit Was	For and on behalf	217,047.61	26,241.99	84,531.57	106,274.05		2,207,00	80 730 3	(1.35)	2,2	7,754,56	2,010.41	2,830,15			42,002,31	10000	42,062.31	14,316.10	27,746.21		Unaudited	31-03-2015	Preceding Quarter ended	9
	or and CFO	f of the Board	210,462.39	Γ	Γ			4,000,-71	2 882 44	(3.71)	2,5	4,931.12	1,010.01	1,030.00	3 000		30,133,30	30 455 00	36,155.98	12,212,73	23,943.25		Unaudited	30-06-2014	Corresponding Quarter ended	e i di
			217,047.61	26,241.99	84,531.57	106,274.05		10,00	15 924 71	(4.80)	0,570.04	24,050,05	24 000 60	5 275 55	10615 14		100,000,00	450 024 QR	100,004,30	47,000.00	108,941.75	200 044 75	Audited	31-03-2015	For the Year ended	

Notes:

- The Financial results have been reviewed by the Audit Committee and taken on record by the Board of Directors at their meeting held on 31st August, 2015
- Statutory Auditors have carried our a "Limited review" of the standalone financial result of the Company for the quarter ended 30th June, 2015
- 3. The figures for the Quarter ended March 31, 2015 are the balancing figures between audited figures in respect of full financial year ended March 31, 2015 and year to date figures upto the third quarter of that financial year.
- Details of Number of Investor complaints for the quarter ended 30th June, 2015: beginning NIL, received- Nil, resolved Nil, pending- NIL as at 30th June, 2015;
- 5. The figures have been re-grouped, re-cast and re-arranged wherever necessary;
- 6. As per clause 41 of the listing agreement, the Company has opted to publish only consolidated financial results. The standalone financial results are available for perusal on the Company's website as well as on the stock exchanges' websites as stated below:

www.dishmangroup.com, www.bseindia.com, and www.nseindia.com.

7 The business segments of the Company comprise the followings:

Segment	Description of the activity
CRAMS	Contract Research and Manufacturing Segment under long term supply agreements
OTHERS	Bulk Drugs, Intermediates, Quats, Speciality Chemicals and Traded Goods

8. Consolidated financial results comprise the results of the parent Company, Dishman Pharmaceuticals and Chemicals Limited and its subsidiaries viz. Dishman Europe Limited., Dishman USA Inc., Dishman International Trading (Shanghai) Co. Ltd., Dishman Switzerland Limited, Dishman Pharma Solutions AG, Switzerland, CARBOGEN AMCIS (Shanghai) Co. Ltd. [formerly known as Dishman Pharmaceuticals & Chemicals (Shanghai) Co. Ltd.], Shanghai Yiqian International Trade Co., Ltd., Innovative Ozone Services Inc. (IO3S), Dishman Netherlands B. V. (formerly known as "Pharma Syn B. V."), Cohecie Fine Chemicals B.V. (formerly known as "Dishman Holland B.V."), Carbogen Amcis Ltd.,U.K. (formerly known as "Synprotec DCR Ltd."), CARBOGEN AMCIS AG, Carbogen Amcis (India) Limited, Dishman Australasia Pty. Ltd., Dishman Care Ltd., Carbogen Amcis SAS, Dishman Middle East (FZE), Dishman Japan Limited, one joint venture Company, namely Schutz Dishman Biotech Ltd.(22.33% holding by Dishman), and one associate company namely, Bhadr-Raj Holdings Pvt. Ltd. (40% holding by Dishman) as per relevant Accounting Standards.

Place: Ahmedabad Date: 31st August, 2015 AHMEDABAD MICHEMAN AHMEDABAD MICHEMAN AHMEDABAD MICHEMAN AHMEDABAD MICHEMAN AHMEDABAD MICHEMAN AMEDICAL AMEDICA

Arpit Vyas
Managing Director & CFO

On behalf of the Board of Directors